Clare Scott

Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk

Iris Kramer, Maartje J Hooning, Nasim Mavaddat, Michael Hauptmann, Renske Keeman, Ewout W Steyerberg, Daniele Giardiello, Antonis C Antoniou, Paul DP Pharoah, Sander Canisius, Zumuruda Abu-Ful, Irene L Andrulis, Hoda Anton-Culver, Kristan J Aronson, Annelie Augustinsson, Heiko Becher, Matthias W Beckmann, Sabine Behrens, Javier Benitez, Marina Bermisheva, et al.

Journal article  |  2020  |  American Journal of Human Genetics

Previous research has shown that polygenic risk scores (PRSs) can be used to stratify women according to their risk of developing ..

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.

RE Miller, A Leary, CL Scott, V Serra, CJ Lord, D Bowtell, DK Chang, DW Garsed, J Jonkers, JA Ledermann, S Nik-Zainal, I Ray-Coquard, SP Shah, X Matias-Guiu, EM Swisher, LR Yates

Journal article  |  2020  |  Annals of Oncology

BACKGROUND: Homologous recombination repair deficiency (HRD) is a frequent feature of high-grade serous ovarian, fallopian tube an..

Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers

Oliver Klein, Damien Kee, Ben Markman, Michael Michael, Craig Underhill, Matteo S Carlino, Louise Jackett, Caroline Lum, Clare Scott, Adnan Nagrial, Andreas Behren, Jane Y So, Jodie Palmer, Jonathan Cebon

Journal article  |  2020  |  Clinical Cancer Research

PURPOSE: Combination immunotherapy with anti-CTLA-4 and anti-PD-1 blockade has demonstrated significant clinical activity across s..

The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients

M Gleeson, M Kentwell, B Meiser, J Do, S Nevin, N Taylor, K Barlow-Stewart, J Kirk, P James, CL Scott, R Williams, K Gamet, J Burke, M Murphy, YC Antill, A Pearn, N Pachter, C Ebzery, N Poplawski, M Friedlander, et al.

Journal article  |  2020  |  Gynecologic Oncology

BACKGROUND: BRCA1/2 mutation status has increasing relevance for ovarian cancer treatments, making traditional coordination of gen..

RNF168-Mediated Ubiquitin Signaling Inhibits the Viability of BRCA1-Null Cancers

John J Krais, Yifan Wang, Andrea J Bernhardy, Emma Clausen, Jessica A Miller, Kathy Q Cai, Clare L Scott, Neil Johnson

Journal article  |  2020  |  Cancer Research

Assessment of PARPi and cisplatin resistance in BRCA1 exon 11 mutant patient -derived xenografts.

John J Krais, Emma Clausen, Vladimir Khazak, Igor Astsaturov, Clare L Scott, Neil Johnson

Conference Proceedings  |  2020  |  CLINICAL CANCER RESEARCH

DNA repair gene promoter methylation patterns adapt and influence PARP inhibitor response.

Kasenija Nesic, Rachel M Hurley, Cordelia McGehee, Olga Kondrashova, Maria I Harrell, Giada V Zapparoli, Ashan Musafer, Ming E Wong, John Weroha, Xiaonan Hou, Hu Li, Vivian Negron, Kevin Peterson, Paula Schneider, Elizabeth M Swisher, Melissa Southey, Alexander Dobrovic, Matthew Wakefield, Scott H Kaufmann, Clare L Scott

Conference Proceedings  |  2020  |  CLINICAL CANCER RESEARCH

Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer.

Elaine Sanij, Katherine Hannan, Jiachen Xuan, Shunfei Yan, Jessica A Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Sarah Ellis, Carleen Cullinane, Gretchen Poortinga, Kum Kum Khanna, Linda Mileshkin, Grant A McArthur, John Soong, Els M Berns, et al.

Journal article  |  2020  |  CLINICAL CANCER RESEARCH

Abstract High-grade serous ovarian cancer (HGSOC) accounts for the majority of ovarian cancer and has a dismal prognosis. PARP inh..

Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer.

Elaine Sanij, Katherine Hannan, Jiachen Xuan, Shunfei Yan, Jessica A Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Sarah Ellis, Carleen Cullinane, Gretchen Poortinga, Kum Kum Khanna, Linda Mileshkin, Grant A McArthur, John Soong, Els M Berns, et al.

Conference Proceedings  |  2020  |  Clinical Cancer Research

Assessment of PARPi and cisplatin resistance in BRCA1 exon 11 mutant patient -derived xenografts.

John J Krais, Emma Clausen, Vladimir Khazak, Igor Astsaturov, Clare L Scott, Neil Johnson

Conference Proceedings  |  2020  |  CLINICAL CANCER RESEARCH